

1 **Title: Influence of landscape patterns on the exposure of LASV across diverse regions**
2 **within the Republic of Guinea**

3 Stephanie Longet*^{1^}, Cristina Leggio*^{2,6}, Joseph Akoi Bore*^{1,3,4,5}, Tom Tipton¹, Yper Hall²,
4 Fara Raymond Koundouno³, Stephanie Key⁶, Hilary Bower⁷, Tapan Bhattacharyya⁶, N’Faly
5 Magassouba⁸, Stephan Günther^{9,10} Ana-Maria Henao-Restrapo¹¹, Jeremy S. Rossman^{5,12},
6 Mandy Kader Konde⁴, Kimberly Fornace^{6,13}, Miles W. Carroll^{1,2^}

7 ¹Nuffield Department of Medicine, University of Oxford, Oxford United Kingdom (S.

8 Longet, J A. Bore, T. Tipton, Miles W. Carroll)

9 ²UK Health Security Agency, Porton Down, Salisbury, United Kingdom (C. Leggio, Y. Hall,

10 Miles W. Carroll)

11 ³Ministry of Health, Conakry, Guinea (J A. Bore, F R. Koundouno)

12 ⁴Center for Training and Research on Priority Diseases including Malaria in Guinea,

13 Conakry, Guinea (J A. Bore, M K. Konde)

14 ⁵University of Kent, School of Biosciences, Canterbury, Kent, United Kingdom (J A. Bore, J

15 S. Rossman)

16 ⁶Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical

17 Medicine, London, United Kingdom (C. Leggio, S. Key, T. Bhattacharyya, K. Fornace)

18 ⁷Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical

19 Medicine, London, United Kingdom (H. Bower)

20 ⁸Projet Laboratoire Fièvres Hémorragiques, Conakry, Guinea (N. Magassouba)

21 ⁹Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (S. Günther)

22 ¹⁰German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems (S.

23 Günther)

24 ¹¹World Health Organisation, Geneva, Switzerland (A-M. Henao-Restrapo)

25 ¹²NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Research-Aid Networks, Chicago, IL, USA (J S. Rossman)

26 ¹³Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow,
27 Glasgow, United Kingdom (K. Fornace)

28

29 *Contributed equally to first authorship

30 ^Corresponding author

31

32 **Abstract – 150 words**

33 Lassa fever virus (LASV) is the causative agent of Lassa fever, a disease endemic in
34 West Africa. Exploring the relationships between environmental factors and LASV
35 transmission across ecologically diverse regions can provide crucial information for the
36 design of appropriate interventions and disease monitoring. We measured LASV-specific IgG
37 seropositivity in 1286 sera collected in Coastal and Forested Guinea. Our results showed that
38 exposure to LASV was heterogenous between the sites. The LASV IgG seropositivity was
39 11.9% (95% CI 9.7-14.5) in Coastal site, while it was 59.6% (95% CI 55.5-63.5) in Forested
40 region. Interestingly, exposure was significantly associated with age, with seropositivity
41 increasing with age in the Coastal site. Finally, we also found significant associations
42 between exposure risk to LASV and landscape fragmentation in Coastal and Forested
43 regions. This study may help to define the regions with an increased exposure risk to LASV
44 where a close surveillance of LASV circulation is needed.

45

46

47

48

49 **Introduction**

50 Lassa virus (LASV) is an enveloped and negative-sense, single-stranded RNA virus
51 belonging to the *Arenaviridae* family causing Lassa Fever (LF) in humans (1). Initial clinical
52 presentation is often non-specific and could be indicative of several other febrile illnesses (2).
53 The mortality rate is unclear due to inconsistent reporting practices and lack of diagnostic
54 services in most endemic areas but estimated to 5-20% in hospitalised patients (2) (3).
55 *Mastomys natalensis* (*M. natalensis*) is considered as the main natural reservoir, a commensal
56 rodent and agricultural pest which aggregates in human dwellings and surrounding fields (4).
57 Recent studies have identified additional rodent reservoirs thus revealing the potential for a
58 wider ecological niche for the virus (5). Both zoonotic and non-zoonotic transmission
59 mechanisms have been described (6). Human LASV infections most commonly occur via
60 infected rodent excreta, through contaminated food and inhalation of aerosols from rodent
61 urine or droppings (7) (8). Less commonly, the virus can be transmitted via nosocomial
62 transmission if proper barrier nursing methods are not followed (6) (9).

63 LASV is endemic in West Africa particularly in Nigeria, Sierra Leone, Liberia and
64 Guinea (10) (11). A published estimate on annual cases of LASV infections in West Africa
65 range from 100,000 to 300,000, with 5,000 to 10,000 estimated deaths per year and 80%
66 asymptomatic infections. Further epidemiological studies are needed as these figures have
67 been extrapolated from one longitudinal study conducted in Sierra Leone in 1987 (12).
68 Increasing evidence suggests LASV is widespread and substantially under-reported by
69 passive surveillance systems (13). Thus, characterising the distribution and transmission
70 intensity of LASV in endemic areas is essential for the design of effective surveillance and
71 disease control programmes.

72 It was observed that patients, including with mild symptoms, induced LASV-specific
73 antibodies including long-lived IgG (14). Consequently, serological methods can measure
74 long-lived antibody responses and enable estimation of cumulative exposure to pathogens
75 (15). The analysis of age-stratified serological responses is a powerful tool to reconstruct
76 historical patterns of transmission and distribution of previously unreported cases (16) (17).
77 Measurement of LASV-antibody responses has been used to detect circulation of LASV
78 across Guinea. Lukashovich *et al* found 25-55% LASV NP-specific IgG positivity among
79 inhabitants of tropical secondary forest and guinea savannah but only 4-7% positivity among
80 inhabitants of mountainous and coastal areas (18). Bausch *et al* investigated the epidemiology
81 and clinical presentation of the Lassa fever in five Guinean hospitals in 2001. Lassa fever
82 suspected cases were tested using an ELISA platform for antibody detection and the analysis
83 confirmed Lassa fever in 22 (7%) of 311 suspected cases. An additional 43 people (14%) had
84 LASV-specific IgG antibodies, indicating past exposure to LASV (19). Another study aiming
85 to estimate the prevalence of Lassa IgG in human population of rural area of Guinea
86 including Guéckédou, Lola and Yomou (Southern region) indicated 12.9% and 10.0 % IgG
87 positivity in rural and urban areas, respectively (7). While these studies describe the historical
88 circulation of LASV across Guinea, these studies were conducted in the 90's and early
89 2000's. The current burden and the distribution of LASV in Guinea is largely unknown.
90 Furthermore, to our knowledge, there are no studies which have estimated transmission
91 intensity from serological data in Guinea and analysed the environmental risk factors. This
92 study aimed to characterise LASV exposure in populations in two ecologically diverse
93 regions of Guinea: the coastal Basse-Guinee region and the forested interior regions of
94 Macenta prefecture and Guéckédou. Here, we describe LASV-specific IgG antibody levels
95 within these populations, estimate transmission intensity using age-stratified antibody
96 responses and explore associations with demographic and environmental risk factors.

97 **Materials and Methods**

98 **Ethical approval**

99 Basse Guinea site (Coastal site): The study was approved by the London School of
100 Hygiene and Tropical Medicine Ethics committee (Ethics Ref: 17429) and the Guinean
101 Ministry of Health (MoH). Macenta site: Ethical approval for research projects in Macenta
102 and Guéckédou (Forested site) on human volunteers was obtained from the ‘Comité national
103 d’éthique pour la recherche en santé’ (CNERs) of Republic of Guinea on the 16th of March
104 2017 (012/CNERS/17).

105 **Study sites**

106 The samples used in this study were initially collected as part of three separate studies
107 focusing on three distinct sites within two geographically diverse regions of Guinea. Basse-
108 Guinee is the coastal region of Guinea, extending for 30-40 miles inland from the Atlantic
109 Ocean to the coastal plains (**Figure 1A**). Macenta prefecture and the city of Guéckédou are
110 located to the south-east of the country, close to the border with Liberia and Sierra Leone,
111 within the forested region of Guinea (**Figure 1A**).

112 **Study participants**

113 Samples from Basse-Guinee were collected in 2016 as part of a clinical trial
114 evaluating the safety and immunogenicity of the VSV-EBOV Ebola Vaccine in partnership
115 with the Guinean MoH, the World Health Organisation (WHO) and Public Health England
116 (PHE). The samples used for our study were taken prior to vaccination. For this study site,
117 702 samples were randomly selected from the PHE/WHO vaccine trial master database by
118 using the Excel random function and tested for the presence of LASV-specific IgG.
119 Information on volunteers age, sex and village of residence provided at the time of
120 vaccination was used. The selected samples, (participants 6-99 years of age) originated from

121 7 prefectures within Basse-Guinee, encompassing 24 subprefectures and 29
122 villages/neighbourhoods.

123 Samples from Macenta region were collected from February to December 2017 as
124 part of a sero-epidemiology study on Ebola virus which included both affected and non-
125 affected villages during the 2014-2016 Ebola Virus Diseases (EVD) outbreak (20). In total,
126 517 participants (17- 90 years of age) living in 44 villages located in 7 subprefectures were
127 enrolled. The volunteers included bush meat hunters, their family members, local health care
128 workers and the general population of the village. Volunteers under 16 years of age, pregnant
129 women, travellers or visitors, and people suffering from chronic disease were excluded from
130 the original study. In total, 516 samples from the Macenta cohort were analysed. For the
131 purpose of the analysis, 68 samples from Guéckédou city, collected in 2018 in the context of
132 a longitudinal study of EVD survivors, were included in the Macenta population. Both
133 Guéckédou city and Macenta prefecture are forested regions. All samples were stored at -
134 80°C in a temperature monitored unit within the PHE Porton Down UK laboratories.
135 Consent forms stating the study aims and their rights as volunteers were signed prior to
136 sample collection for each individual study.

137 **Blood sample collection and processing**

138 A volume (5-20ml) of human peripheral blood was collected into non-anticoagulant
139 BD Vacutainer® blood collection tubes from participants. Blood clotted within two hours and
140 transported to the laboratory in a cool box at 4°C. Samples were centrifuged at 2,000 x g for
141 10 minutes at room temperature and serum aliquoted into 2 ml microtube RT-PCR tubes
142 (Starsted, REF 72.694.406) in an air purifying class II microbiological safety cabinet (Envair
143 Ltd, England). Aliquots of sera were shipped on dry ice at -20°C and processed at PHE
144 Porton Down laboratories (England).

145 **Samples analysis by LASV-specific ELISA**

146 To measure anti-LASV IgG specific antibodies in sera, the patented BLACKBOX[®]
147 LASV IgG kit from Bernhard Nocht Institute for Tropical Medicine (BNITM) in Germany
148 (ELG.004) used for qualitative serological detection of acute or past LASV infection (21)
149 (22). The kit was used as per the manufacturer's instructions. Each sample was run as single
150 replicate. All reagents were provided by BNITM. Positive and negative controls were
151 provided with the kit. Blank and background wells were added to monitor non-specific
152 bindings of proteins to reagent contaminants or to the ELISA plate surface. Briefly, initial
153 plate washing was performed using pre-diluted wash buffer. Then, 25uL of diluted
154 biotinylated recombinant LASV antigen (nucleoprotein) were transferred onto the ELISA
155 plate and 25uL of diluted control or patient sample added prior to plate incubation for 24h at
156 4°C in a humid chamber. After a wash step, 50uL of diluted streptavidin/Horseradish
157 Peroxidase (HRP) were added and plate incubated for 1h at 4°C. Another wash step was
158 performed, 100uL/well of 3,3',5,5'-Tetramethylbenzidine (TMB) peroxidase substrate were
159 added and plate incubated for 10min at room temperature in the dark. Finally, 100uL/well of
160 Stop solution (1M H₂SO₄) were added and optical density (OD) readings (450-620nm)
161 obtained by using SpectraMax plate reader (software SoftMaxPro v9). As recommended in
162 the BLACKBOX[®] LASV IgG ELISA manual, results were interpreted as valid if the
163 following criteria were met: OD₄₅₀-OD₆₂₀ of negative control < 0.10 and OD₄₅₀-OD₆₂₀ of
164 positive control > 1.00. Average absolute OD₄₅₀-OD₆₂₀ absorbance value for negative
165 control samples ($OD_{Neg,AV}$) was used to calculate the assay cut off OD_{CO} according to the
166 following formula:

$$167 \quad OD_{Neg,AV} + 0.150 = OD_{CO}$$

168 Index Values (IV) for the tested samples were calculated as follows:

169 $IV_{sample} = OD_{450} - OD_{620} (\text{sample}) / OD_{CO}$

170 Results classification for index values was carried out as follows:

171 $IV_{sample} \geq 1.00 = \text{POSITIVE}$

172 $0.90 < IV_{sample} < 1.00 = \text{EQUIVOCAL}$

173 $IV_{sample} \leq 0.90 = \text{NEGATIVE}$

174 **Environmental and spatial covariates**

175 To assess the impact of land cover and other environmental covariates on LASV
176 exposure, we assembled a dataset of remote-sensing derived land cover maps from 2017 at
177 100m resolution (23). We reclassified land cover into the following categories: closed forest
178 (canopy cover >70%), open forest (canopy cover 15-70%), shrubs, herbaceous vegetation
179 (plants without persistent stems and canopy cover <10%) and urban/built up areas. We
180 additionally extracted data on the percentage canopy cover for all sites. Population density
181 was obtained from village level population estimates of all sampled areas.

182 As sampled villages were only geolocated to centroids, we extracted environmental
183 data within buffer radii of 500m, 1km, 2km, 5km and 10km from the village centroid to
184 represent the possible distributions of the village and lands used (24). For all buffer radii, we
185 extracted the proportions of different land cover types and the mean canopy cover. To
186 evaluate the importance of landscape configuration, we additionally extracted metrics on
187 fragmentation, including perimeter area ratio, shape index (patch perimeter divided by the
188 minimum possible patch perimeter) and fractal dimension index (an index of shape
189 complexity) (25). In ecology, fragmentation is defined as the breaking up of habitat and it is
190 often used as a measurable index, usually related to human activity, which produces loss or
191 reduction in habitat size or increased isolation of habitats.

192 **Statistical analyses**

193 To characterise transmission intensity in both sites, we first graphed both continuous
194 antibody responses and age-specific estimates of seropositivity. Reversible catalytic models
195 were fit to age sero-prevalence data using maximum likelihood methods (15). We used
196 profile likelihood plots to explore possible historical changes in transmission intensity, with
197 final models selected using likelihood ratio tests (26). Final models were used to estimate
198 seroconversion rates (SCR).

199 We additionally assessed whether fine-scale patterns of serological exposure were
200 associated with landscape characteristics. As environmental variables can be associated with
201 risk at different spatial scales, we used a data-driven approach to identify environmental risk
202 factors (27). First, mixed-effects logistic regression models were run for each environmental
203 variable at each spatial scale (126 in total) to identify factors associated with LASV
204 seropositivity. Models were run separately for both sites, with the primary outcome as the
205 binary classification for individual level seropositivity. Models were fit with village as a
206 random effect to account for observations within villages lacking independence. We first
207 assessed associations with key demographic factors, including gender, continuous age and
208 age category. For the Macenta/Guéckédou (forested region) model, only environmental
209 predictors were included as demographic factors (age, gender) were not associated with
210 exposure risks. For the coastal site, age category was included in all models in addition to
211 environmental predictors. When assessing for inclusion in the multivariate analysis,
212 univariate results were considered significant at $p < 0.2$ to avoid exclusion of variables that
213 alone lack significance but contribute in presence of other variables. Highly correlated
214 variables (Pearson's correlation coefficient > 0.75) were removed. Where environmental
215 covariates appeared significantly associated with the outcome of interest across multiple
216 buffer radii, inclusion in the final model was based on Akaike's Information Criteria (AIC).

217 Final multivariate models were fit in a forward stepwise manner using AIC, with variables
218 considered significant at $p < 0.05$.

219 Results

220 Within this study, we assessed LASV IgG seropositivity in 1286 individuals using
221 serum samples collected from the period of 2016 to 2018 in Guinea. In the Coastal site, 702
222 samples were analysed from 7 prefectures, encompassing 24 subprefectures and 29
223 villages/neighbourhoods (**Figure 1A, Table 1, Appendix Table 1**). In the Forested site, 516
224 samples were analysed from Macenta prefecture and 68 from Guéckédou city. The Macenta
225 samples originated from 7 subprefectures encompassing 44 villages (**Figure 1A, Table 1,**
226 **Appendix Table 2**).

| Coastal site | | Forested Region | |
|-------------------|-------------|-------------------|-------------|
| N | 702 | N | 584 |
| | | Macenta | 516 |
| | | Guéckédou | 68 |
| Female | 243 (34.6%) | Female | 262 (44.9%) |
| Male | 459 (65.4%) | Male | 322 (51.1%) |
| Age range (years) | 6-99 | Age range (years) | 17-90 |
| Mean age (years) | 32.3 | Mean age (years) | 38.8 |
| Sampling dates | 2016 | Sampling dates | 2017-2018 |

227 **Table 1:** Study participants of coastal and forested regions.

228 We observed that exposure to LASV was highly heterogenous both between (**Figure 1A**) and
229 within (**Figure 1B**) each study site. The LASV IgG seropositivity was 11.9% (95% CI 9.7-

230 14.5) in the Coastal site (**Figure 1B, Appendix Table 1**), while it was 59.6% (95% CI 55.5-
231 63.5) in the Forested site (**Figure 1B, Appendix Table 2**).

232

A.



233

234

235

236

237

238


239

240

241

242

B.




243

244 **Figure 1: A)** Map of West Africa and Guinea showing the study sites: Coastal and Forested
245 sites. **B)** LASV-specific IgG seropositivity (%) by village across the Coastal and Forested
246 sites.

247 Demographic characteristics of exposed individuals varied by study site. In the
248 Coastal site, seropositivity in females was 9.0% (95% CI 5.8-13.1) and in males was 13.5%
249 (95% CI 11.0-17.0). For the Forested site, seropositivity in females was 61.8% (95% CI 56.0-
250 67.7) and in males was 58% (95% CI 52.5-63.3). Gender was not significantly associated
251 with seropositivity in either site.

252 Age patterns of seropositivity differed markedly between sites. In the Coastal site,
253 exposure was strongly associated with age, with seropositivity increasing with age (**Figure**

254 **2A**). However, no correlation was found between the quantitative antibody responses
255 expressed by Index Value and age among seropositive individuals (**Appendix Figure 1**).
256 Within this population, reversible catalytic models estimated the force of infection
257 (Seroconversion rate = SCR) as 0.0041 (95% CI: 0.0033 – 0.0050). No changes in historical
258 transmission intensity were detected ($p = 0.328$). In contrast, within the Forested site, no clear
259 age patterns were identified and neither continuous nor categorical age were associated with
260 individual seropositivity (**Figure 2B**). Although age ranges for included individuals were
261 different between both sites (**Table 1**), substantial differences in exposure risks were detected
262 in similar age groups between sites. For example, individuals aged 17-20 had an estimated
263 seropositivity of 5.4% (95% CI: 1.5-13.3%) in the Coastal site compared to 50.0% in the
264 Forested site (95% CI: 37.2 – 62.8%). The high proportions of seropositivity in the youngest
265 age groups and lack of association with age precluded fitting reversible catalytic models for
266 the Forested region.




267 **Figure 2.** Proportion seropositive with 95% Confidence intervals by age decile for Coastal
268 site (**A**) and Forested site (**B**), blue line is modelled SCR curve.
269

270


271 Despite clear differences in transmission between sites, strong associations between
272 exposure and environmental factors were identified for both sites. The land cover classes for
273 both sites are shown in **Figure 3A**. As characterised by perimeter area ratios, fragmentation
274 was strongly positively associated with exposure risk for both sites (**Figure 3B and C**,
275 **Appendix Tables 3 and 4**). In the Coastal site, the proportion of open forests and
276 fragmentation of built up areas increased odds of exposure. Other land cover factors, such as
277 closed forests and vegetation fragmentation, were not significantly associated with exposure
278 risks but improved overall model fit (**Figure 3B, Appendix Table 3**). Within the Forested
279 site, increased fragmentation of both open and closed forests was positively associated with
280 risk, while fragmented vegetation was protective (**Figure 3C, Appendix Table 4**). Across
281 both sites, significant variables were identified at different spatial scales, consistent with
282 other studies of environmental risk factors for zoonotic diseases (28).

283 **A.**



291

292



298 **Figure 3: A)** Land cover classes for the Coastal and Forested sites. **B and C)** Associations
 299 between exposure risk and environmental factors in the Coastal (**B**) and Forested sites (**C**).
 300 OR: Odd ratios. CI: Confidence intervals.

301 Discussion

302 Despite the growing interest in Lassa fever, there is limited up-to-date information
 303 regarding the seropositivity of LASV in West Africa. To our knowledge, this study is the first
 304 one to estimate transmission intensity from serological data in Guinea and analyse the
 305 environmental risk factors. We found that LASV NP-specific IgG seropositivity differed
 306 between our study sites: Coastal and Forested regions. In 1993, Lukashevich and colleagues
 307 had also found a high LASV NP-specific IgG positivity among inhabitants of tropical
 308 secondary forest (areas near Guéckédou, Yomou, and Lola) and guinea savannah (Faranah
 309 and Kindia areas) (25-55%) and a lower positivity among inhabitants of mountainous (Pita,
 310 Labe, and Mali) and coastal areas (Boffa, Boké) (4-7%) (18). In our study, we found that
 311 gender was not significantly associated with seropositivity in either site, which is in line with
 312 other studies conducted both in Guinea and Sierra Leone (18) (12). Interestingly, our findings
 313 showed a significant increase in LASV IgG seropositivity with age in the Coastal site but not
 314 in the Forested site. Although in the above-mentioned study, Lukashevich and colleagues did
 315 not detect any correlation between antibody prevalence and age in any studied regions (18),

316 differences in age patterns of seropositivity between regions were observed in other studies in
317 West Africa. A study conducted in Forested Guinea in the year 2000, found individuals under
318 10 and between 20 and 29 years of age to have the highest LASV IgG prevalence (7). A
319 study conducted in Sierra Leone, found antibody prevalence to increase with age, reaching a
320 peak at 20-50 years of age and decreasing thereafter (12). A similar trend was reported in
321 another pilot study conducted in 2015 in Nigeria (29). Age, often associated with occupation
322 or daily activities, may play a role on exposure but our results in the forested region and
323 others studies suggest that in some regions, other factors such as environmental features may
324 have a bigger impact on exposure risk. It is also possible that more localised exposure within
325 the household plays a role for viral transmission. Finally, we found an association between
326 landscape patterns and exposure risk for both study sites. Associations between landscape
327 fragmentation and exposure risk to zoonotic diseases have been observed for other zoonotic
328 diseases such as malaria (28) (30) and Ebola virus (31). In our study, the fragmentation of
329 forests and their proportion appear to have an impact on exposure risk but their exact role in
330 the complex dynamics of LASV circulation remains to be determined.

331 The murine population is another variable involved in the distribution of LASV. In
332 one study looking at LASV-specific IgG prevalence in the reservoir host *M. natalensis* in
333 Guinea, the authors found that 0% of the *M. natalensis* were infected with Lassa virus in the
334 low seroprevalence area (the coastal region) while 5.4%-32.1 % of sampled mice were
335 infected with the virus in the high seroprevalence region (forested guinea) (10). Another
336 study sampled a total of 1616 small rodents (956 *Mastomys* sp.) captured in 444 households
337 in the savanna, mixed savanna-forest and forest region of Guinea were studied for LASV-
338 specific antibody and antigen detection. The authors found that the proportion of LASV
339 infected rodents per region ranged from 0% - 9%. It was higher in the savannah and forested
340 areas. Interestingly, they observed that the proportion of infected animals in each village was

341 highly variable amongst neighboring villages, identifying ‘hot spots’ of LASV infected mice
342 clustering within few homes, thus adding a further element that could drive the highly
343 heterogeneous distribution of LASV (32). Even though the distribution of *M. natalensis* is an
344 important factor, its presence may not be sufficient to explain the IgG seropositivity in
345 humans (33) (10), as additional rodent reservoirs have been identified revealing the potential
346 for a wider ecological niche for LASV (5).

347 Finally, some limitations of our study can be highlighted. The type of ELISA used to
348 assess LASV seropositivity may impact on the results. Even though the BLACKBOX IgG
349 ELISA was shown to be sensitive and very specific (90% and 99%) when compared to the
350 immunofluorescence assay (21), it was not tested against other arenaviruses due to lack of
351 suitable serum panels. Consequently, we cannot fully exclude the potential circulation of
352 related, or perhaps yet undescribed arenaviruses, in specific regions (34) and a partial cross-
353 reactivity of IgG antibodies against other arenaviruses. In addition, as the samples were
354 collected as part of a vaccine evaluation and a sero-epidemiology study on Ebola virus, the
355 sampling procedure was not standardised between the studies. It would have been useful to
356 have additional information on individual’s LASV exposure risks i.e. occupation, relevant
357 medical history, hunting/foraging habits, location of previous residence, methods for food
358 storage and rodents trapping around the house. It would be useful to know the number of
359 people in the household, the quality of the building, as well as presence of rodent burrows in
360 or around the house. Finally, this study measured only IgG antibodies in sera collected at one
361 timepoint. As such, our data does not allow us to capture the potential effect of changes in
362 seasonal rodent activity or vegetation patterns surrounding the villages. Also, since people
363 tend to move frequently across wide regions, either to find work during harvest season or to
364 hunt (35) and some may have moved away from Ebola virus disease hotspots during the

365 2013-2016 outbreak, they may have been exposed to LASV in a different location from the
366 one in which they resided at the time of sampling.

367 Similar to other endemic tropical diseases, LASV dynamics result from complex
368 interactions between several human and environmental factors. Our study compared the
369 LASV-specific IgG seropositivity in Coastal and Forested regions in Guinea and for the first
370 time described in detail association between exposure to LASV and landscape patterns.
371 Enhanced knowledge of regions with an a potentially increased exposure risk to LASV can
372 help to improve the epidemiological surveillance, devise one health interventions and
373 highlight potential trial sites to assess new LASV vaccines and therapeutics.

374 **Acknowledgments**

375 This work was funded by the US Food & Drug Administration (HHSF223201510104C)
376 and the CGIAR Research Program on Agriculture for Nutrition and Health (A4NH). SG was
377 supported by grants GU883/5-1 and GU883/5-2 from the German Research Foundation (DFG).
378 KMF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and
379 the Royal Society (Grant no. 221963/Z/20/Z).

380 **References**

- 381 1. Hensley, L.E.; Smith, M.A.; Geisbert, J.B.; Fritz, E.A.; Daddario-DiCaprio, K.M.;
382 Larsen, T.; et al. Pathogenesis of Lassa fever in cynomolgus macaques. *Virology* 2011,
383 8, 205.
- 384 2. Richmond, J.K.; Baglolle, D.J. Lassa fever: epidemiology, clinical features, and social
385 consequences. *BMJ* 2003, 327, 1271-1275.
- 386 3. McCormick, J.B.; Walker, D.H.; King, I.J.; Webb, P.A.; Elliott, L.H.; Whitfield, S.G.;
387 et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. *Am J Trop Med
388 Hyg* 1986, 35, 401-407.

- 389 4. Monath, T.P.; Newhouse, V.F.; Kemp, G.E.; Setzer, H.W.; Cacciapuoti, A. Lassa
390 virus isolation from *Mastomys natalensis* rodents during an epidemic in Sierra Leone.
391 *Science* 1974, 185, 263-265.
- 392 5. Olayemi, A.; Oyeyiola, A.; Obadare, A.; Igbokwe, J.; Adesina, A.S.; Onwe, F.; et al.
393 Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria.
394 *Parasit Vectors* 2018, 11, 416.
- 395 6. Fisher-Hoch, S.P.; Tomori, O.; Nasidi, A.; Perez-Oronoz, G.I.; Fakile, Y.; Hutwagner,
396 L.; et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor
397 medical practice. *BMJ* 1995, 311, 857-859.
- 398 7. Kerneis, S.; Koivogui, L.; Magassouba, N.; Koulemou, K.; Lewis, R.; Aplogan, A.; et
399 al. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest
400 region of Guinea: a cross-sectional study. *PLoS Negl Trop Dis* 2009, 3, e548.
- 401 8. Stephenson, E.H.; Larson, E.W.; Dominik, J.W. Effect of environmental factors on
402 aerosol-induced Lassa virus infection. *J Med Virol* 1984, 14, 295-303.
- 403 9. Ajayi, N.A.; Nwigwe, C.G.; Azuogu, B.N.; Onyire, B.N.; Nwonwu, E.U.;
404 Ogonnaya, L.U.; et al. Containing a Lassa fever epidemic in a resource-limited
405 setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-
406 March 2012). *Int J Infect Dis* 2013, 17, e1011-1016.
- 407 10. Lecompte, E.; Fichet-Calvet, E.; Daffis, S.; Koulemou, K.; Sylla, O.; Kourouma, F.;
408 et al. *Mastomys natalensis* and Lassa fever, West Africa. *Emerg Infect Dis* 2006, 12,
409 1971-1974.
- 410 11. Ogbu, O.; Ajuluchukwu, E.; Uneke, C.J. Lassa fever in West African sub-region: an
411 overview. *J Vector Borne Dis* 2007, 44, 1-11.

- 412 12. McCormick, J.B.; Webb, P.A.; Krebs, J.W.; Johnson, K.M.; Smith, E.S. A
413 prospective study of the epidemiology and ecology of Lassa fever. *J Infect Dis* 1987,
414 155, 437-444.
- 415 13. Gibb, R.; Moses, L.M.; Redding, D.W.; Jones, K.E. Understanding the cryptic nature
416 of Lassa fever in West Africa. *Pathog Glob Health* 2017, 111, 276-288.
- 417 14. Bond, N.; Schieffelin, J.S.; Moses, L.M.; Bennett, A.J.; Bausch, D.G. A historical
418 look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute
419 infection. *Am J Trop Med Hyg* 2013, 88, 241-244.
- 420 15. Drakeley, C.J.; Corran, P.H.; Coleman, P.G.; Tongren, J.E.; McDonald, S.L.;
421 Carneiro, I.; et al. Estimating medium- and long-term trends in malaria transmission
422 by using serological markers of malaria exposure. *Proc Natl Acad Sci U S A* 2005,
423 102, 5108-5113.
- 424 16. Greenhouse, B.; Daily, J.; Guinovart, C.; Goncalves, B.; Beeson, J.; Bell, D.; et al.
425 Priority use cases for antibody-detecting assays of recent malaria exposure as tools to
426 achieve and sustain malaria elimination. *Gates Open Res* 2019, 3, 131.
- 427 17. Arnold, B.F.; Scobie, H.M.; Priest, J.W.; Lammie, P.J. Integrated Serologic
428 Surveillance of Population Immunity and Disease Transmission. *Emerg Infect Dis*
429 2018, 24, 1188-1194.
- 430 18. Lukashevich, I.S.; Clegg, J.C.; Sidibe, K. Lassa virus activity in Guinea: distribution
431 of human antiviral antibody defined using enzyme-linked immunosorbent assay with
432 recombinant antigen. *J Med Virol* 1993, 40, 210-217.
- 433 19. Bausch, D.G.; Demby, A.H.; Coulibaly, M.; Kanu, J.; Goba, A.; Bah, A.; et al. Lassa
434 fever in Guinea: I. Epidemiology of human disease and clinical observations. *Vector*
435 *Borne Zoonotic Dis* 2001, 1, 269-281.

- 436 20. Thom, R.; Tipton, T.; Strecker, T.; Hall, Y.; Akoi Bore, J.; Maes, P.; et al.
437 Longitudinal antibody and T cell responses in Ebola virus disease survivors and
438 contacts: an observational cohort study. *Lancet Infect Dis* 2021, 21, 507-516.
- 439 21. Gabriel, M.; Adomeh, D.I.; Ehimuan, J.; Oyakhilome, J.; Omomoh, E.O.; Ighodalo,
440 Y.; et al. Development and evaluation of antibody-capture immunoassays for
441 detection of Lassa virus nucleoprotein-specific immunoglobulin M and G. *PLoS Negl*
442 *Trop Dis* 2018, 12, e0006361.
- 443 22. Schmitz, H.; Gabriel, M.; Emmerich, P. Specific detection of antibodies to different
444 flaviviruses using a new immune complex ELISA. *Med Microbiol Immunol* 2011,
445 200, 233-239.
- 446 23. Buchhorn, M.; Smets, B.; Bertels, L.; De Roo, B.; Lesiv, M.; Tsendbazar, N.-E.; et al.
447 Copernicus Global Land Service: Land Cover 100m: collection 3: epoch 2019: Globe.
448 Zenodo 2020.
- 449 24. Brock, P.M.; Fornace, K.M.; Grigg, M.J.; Anstey, N.M.; William, T.; Cox, J.; et al.
450 Predictive analysis across spatial scales links zoonotic malaria to deforestation. *Proc*
451 *Biol Sci* 2019, 286, 20182351.
- 452 25. McGarigal, K.; Cushman, S.; Catherine Neel, M.; E., E. Spatial Pattern Analysis
453 Program for Categorical Maps. Available online:
454 www.umass.edu/landeco/research/fragstats/fragstats.html
- 455 26. Stewart, L.; Gosling, R.; Griffin, J.; Gesase, S.; Campo, J.; Hashim, R.; et al. Rapid
456 assessment of malaria transmission using age-specific sero-conversion rates. *PLoS*
457 *One* 2009, 4, e6083.
- 458 27. Fornace, K.M.; Brock, P.M.; Abidin, T.R.; Grignard, L.; Herman, L.S.; Chua, T.H.; et
459 al. Environmental risk factors and exposure to the zoonotic malaria parasite

- 460 Plasmodium knowlesi across northern Sabah, Malaysia: a population-based cross-
461 sectional survey. *Lancet Planet Health* 2019, 3, e179-e186.
- 462 28. Stefani, A.; Dusfour, I.; Correa, A.P.; Cruz, M.C.; Dessay, N.; Galardo, A.K.; et al.
463 Land cover, land use and malaria in the Amazon: a systematic literature review of
464 studies using remotely sensed data. *Malar J* 2013, 12, 192.
- 465 29. Tobin, E.; Asogun, D.; Akpede, N.; Adomeh, D.; Odia, I.; Gunther, S. Lassa fever in
466 Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study.
467 *J Med Trop* 2015, 17, 51-55.
- 468 30. Fornace, K.M.; Abidin, T.R.; Alexander, N.; Brock, P.; Grigg, M.J.; Murphy, A.; et
469 al. Association between Landscape Factors and Spatial Patterns of Plasmodium
470 knowlesi Infections in Sabah, Malaysia. *Emerg Infect Dis* 2016, 22, 201-208.
- 471 31. Olivero, J.; Fa, J.E.; Real, R.; Marquez, A.L.; Farfan, M.A.; Vargas, J.M.; et al.
472 Recent loss of closed forests is associated with Ebola virus disease outbreaks. *Sci Rep*
473 2017, 7, 14291.
- 474 32. Demby, A.H.; Inapogui, A.; Kargbo, K.; Koninga, J.; Kourouma, K.; Kanu, J.; et al.
475 Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in
476 small mammals. *Vector Borne Zoonotic Dis* 2001, 1, 283-297.
- 477 33. Marien, J.; Kourouma, F.; Magassouba, N.; Leirs, H.; Fichet-Calvet, E. Movement
478 Patterns of Small Rodents in Lassa Fever-Endemic Villages in Guinea. *Ecohealth*
479 2018, 15, 348-359.
- 480 34. Coulibaly-N'Golo, D.; Allali, B.; Kouassi, S.K.; Fichet-Calvet, E.; Becker-Ziaja, B.;
481 Rieger, T.; et al. Novel arenavirus sequences in *Hylomyscus* sp. and *Mus* (*Nannomys*)
482 *setulosus* from Cote d'Ivoire: implications for evolution of arenaviruses in Africa.
483 *PLoS One* 2011, 6, e20893.

484 35. Mari Saez, A.; Cherif Haidara, M.; Camara, A.; Kourouma, F.; Sage, M.;
485 Magassouba, N.; et al. Rodent control to fight Lassa fever: Evaluation and lessons
486 learned from a 4-year study in Upper Guinea. PLoS Negl Trop Dis 2018, 12,
487 e0006829.

488

489 Address for correspondence: Prof Miles W. Carroll & Dr Stephanie Longet, Nuffield
490 Department of Medicine, Wellcome Centre for Human Genetics, University of Oxford,
491 Oxford, OX3 7BN, United Kingdom. Emails and phone numbers:
492 miles.carroll@ndm.ox.ac.uk (+447920232324) and
493 stephanie.longet@well.ox.ac.uk (+441865617892).

494

495